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This paper aims to present an overview of MICA and natural killer group 2 member 
D (NKG2D) genetic and functional interactions and their impact on kidney transplant 
outcome. Organ transplantation has gone from what can accurately be called a “clinical 
experiment” to a routine and reliable practice, which has proven to be clinically relevant, 
life-saving and cost-effective when compared with non-transplantation management 
strategies of both chronic and acute end-stage organ failures. The kidney is the most 
frequently transplanted organ in the world (transplant-observatory1). The two treatment 
options for end-stage renal disease (ESRD) are dialysis and/or transplantation. Compared 
with dialysis, transplantation is associated with significant improvements in quality of 
life and overall longevity. A strong relationship exists between allograft loss and human 
leukocyte antigens (HLA) antibodies (Abs). HLA Abs are not the only factor involved in 
graft loss, as multiple studies have shown that non-HLA antigens are also involved, even 
when a patient has a good HLA matche and receives standard immunosuppressive 
therapy. A deeper understanding of other biomarkers is therefore important, as it is 
likely to lead to better monitoring (and consequent success) of organ transplants. The 
objective is to fill the void left by extensive reviews that do not often dive this deep into 
the importance of MICA and NKG2D in allograft acceptance and their partnership in the 
immune response. There are few papers that explore the relationship between these 
two protagonists when it comes to kidney transplantation. This is especially true for the 
role of NKG2D in kidney transplantation. These reasons give a special importance to this 
review, which aims to be a helpful tool in the hands of researchers in this field.
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iNTRODUCTiON
Genetic diversity is the hallmark of MHC genes (1). The main antigenic barrier to transplantation 
is molecules, which are polypeptide products of a cluster of genes known, in humans, as human 
leukocyte antigens (HLA). In addition, a family of highly glycosylated MHC-encoded molecules, 
the MHC class I chain-related (MIC) genes, has been identified (2) as a second lineage of mammalian 
MHC I genes, which could constitute an antigenic barrier to transplantation as well (3). The MIC 
molecules possess a low degree of homology to other MHC class I encoded genes and interact with 
1 http://www.transplant-observatory.org.
FiGURe 1 | Representation of MHC class I chain-related (MIC) genes. The functional genes are represented in green and the pseudogenes are in orange 
(image by Matilde Risti).
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both T-cell and natural killer (NK)-cell receptors (2). MIC pro-
teins act as ligands for NK cells, γδ T cells, and αβ CD8+ T cells, 
which express natural killer group 2 member D (NKG2D) ligand 
(4). The importance of the MICA protein in kidney transplanta-
tion has been acknowledged in recent years, and the role they play 
in graft rejection has been intensely pursued.
MICA GeNe: STRUCTURe, 
POLYMORPHiSMS, AND FUNCTiON
The MIC gene family consists of seven members (MICA–MICG) 
(Figure 1), five of which are pseudogenes, and two, MICA and 
MICB, of which are functional (5, 6). MICA and MICB are the 
most divergent members of the human MHC-encoded class I 
genes identified to date, having an average of 19, 25, and 35% 
similarity in the extracellular α1, α2, and α3 domains, respec-
tively, to those of other MHC α-polypeptides (7).
The MICA gene is located 46.4 kb centromeric to HLA–B on 
the short (p) arm of chromosome 6 at position 21.33 (3).
MICA and MICB have been shown to differ in the tran-
scriptional control regions from common HLA class I genes. 
MICA/B genes lack the prototypic MHC class I gene promoter 
regulatory elements, the SXY module [heterotrimeric X-box-
binding factor—regulatory factor X; X2-box-binding factor—
cyclic-AMP-responsive-element-binding protein; Y-box-binding 
factor—nuclear transcription factor Y (NF-Y); and an as-yet-
unidentified S-box-binding factor]. In contrast, the regulatory 
promoter module of MICA/B contains heat shock elements 
resembling those of HSP70 genes, a CCAAT box that binds to 
nuclear transcription factor Y (NF-Y), and a GC box that binds 
to Sp1, Sp3, and Sp4 transcription factors (8).
There are 12 known possible haplotypes of MICA 5′ promoter 
regions, including a null haplotype due to a deletion of the entire 
MICA gene (MICA-P12), which are more densely distributed in 
both ends compared to the central portion of 5′ promoter (8, 9).
MICA has six exons separated by five introns (Figure 2): exon 
1 encodes the leader peptide, exons 2–4 encode three extracellular 
globular domains, exon 5 encodes the transmembrane domain, 
and exon 6 encodes the cytoplasmatic tail (6, 10). An intron of 
6,840 bp follows exon 1 and is unusually large for a class I gene. 
The remainder of the MICA gene has a quite similar organization 
to classical class I genes, except for the presence of a relatively 
long intron 5 and the fusion of the cytoplasmic tail and 3′ UTR 
sequence in a single last exon (11).
It is considered that MICA gene has a codominant expression, 
and the presence of heat shock elements within the promoter 
suggests that MICA transcription is indued under stress condi-
tions, and that therefore the MICA protein functions as an 
indicator of cell stress (11–13). The first intron of the MICA gene 
contains an NFkB-binding site that binds p65 (RelA)/p50 het-
erodimers and p50/p50 homodimers of the NFkB transcription 
factor family. The role of the proximal −130 bp NFkB site was 
reported as necessary and sufficient for transcriptional transacti-
vation of MICA in response to TNFα in primary endothelial cells 
(ECs) (14).
Gene transcription isoforms are mRNAs transcribed from the 
same locus that differs in their transcription start sites and/or 
untranslated regions or protein coding DNA sequences (CDSs) 
also producing different protein isoforms. The alternative splicing 
of MICA leads to the formation of four isoforms. Two of them 
were described by Zou and Stastny (15) (MICA isoforms 1 and 
2), and they did not appear to be tissue specific.
MICA isoform 1 (1*001) is the longest isoform, derived from 
the MICA*001 allele. MICA isoform 2 (1*008:01) is a variant 
isoform derived from the MICA*008:01 allele that contains a 
four-nucleotide insertion (rs9279200), which causes a frameshift 
mutation and subsequent truncation of the CDS, compared 
to isoform 1 (allele MICA*001) (15). The other two isoforms 
of MICA, isoforms 3 and 4, are described only in the ncbi.nih.
gov/gene2 website. MICA isoform 3 is, like isoform 2, encoded 
by the MICA*008:01 allele; however, it is shorter than isoform 
2 at the N-terminus, containing an alternate 5′ exon, differences 
in the 5′ UTR, and lacking a portion of the 5′ coding region, 
with translation being initiated from a downstream in frame 
start codon. MICA isoform 4 contains an alternate 5′ exon and 
uses an alternate splice site in an internal exon. It differs in the 
5′ UTR, lacks a portion of the 5′ coding region, and initiates 
translation from an alternate start codon, compared to variant 
1 (MICA*008:01 allele). Isoform 4 has a distinct and shorter 
N-terminus, compared to isoform 2.
The MIC genes are transcribed in keratinocytes, ECs, fibro-
blasts, monocytes, epithelial cell lines and epithelial tissues of cell 
lines, and freshly isolated cells (2, 16) and are not usually tran-
scribed in CD4+ T cells, CD8+ T cells, and CD19+ cells (17). MIC 
protein is only expressed on the cell surface of freshly isolated 
ECs, fibroblasts (17), and gastric epithelium (12). MIC protein 
acts as a ligand for NK cells, γδ T cells, and αβ CD8+ T cells, which 
express NKG2D ligand (NKG2DL) (4).
2 https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&T
erm=100507436#.
TAbLe 1 | Nucleotide variations on exons 2–6 for MICA alleles from *001 
to *087.
eXON 2 α1
CODON 6 CTG (LEU) CGC (ARG)
CTC (PRO)
CODON 14 TGG (TRP) GGG (GLY)
CODON 23 CTC (LEU) GTT (LEU)
CODON 24 ACT (THR) GCT (VAL)
CODON 26 GTA (VAL) GGA (GLY)
CODON 36 TGT (CYS) TAT (TYR)
CODON 38 AGG (ARG) AGC (SER)
CODON 39 CAG (GLN) TAG (Stop)
CODON 55 GGA (GLY) GGC (GLY)
CODON 56 AAT (ASN) AAC (ASN)
CODON 64 AGA (ARG) AAG (ARG)
CODON 69 AAC (ASN) AAT (ASN)
eXON 3 α2
CODON 90 CTC (LEU) TTC (PHE)
CODON 91 CAG (GLN) CGG (ARG)
CODON 93 ATT (ILE) ATG (MET)
CODON 102 AAC (ASN) AGC (SER)
CODON 105 AAG (ARG) AAG (LYS)
CODON 112 TAC (TYR) TAT (TYR)
CODON 114 GGG (GLY) AGG (ARG)
CODON 122 CTG (LEU) GTG (VAL)
CODON 124 ACT (THR) TCT (SER)
CODON 125 AAG (LYS) GAG (GLU)
CODON 129 ATG (MET) GTG (VAL)
CODON 130 CCC (PRO) TCC (SER)
CODON 139 GCC (ALA) GCA (ALA)
CODON 142 GTC (VAL) ATC (ILE)
CODON 151 ATG (MET) GTG (VAL)
CODON 156 CAC (HIS) CTC (LEU)
CGC (ARG)
CODON 169 CGG (ARG) TGG (TRP)
CODON 173 AAA (LYS) GAA (GLU)
CODON 174 TCC (SER) TCT (SER)
CODON 175 GGC (GLY) AGC (SER)
GGT (GLY)
CODON 176 GTA (VAL) ATA (ILE)
CODON 181 ACA (THR) AGA (ARG)
eXON 4 α3
CODON 190 CGC (ARG) TGC (CYS)
CODON 191 AGC (SER) AGT (SER)
CODON 193 GCC (ALA) GCA (ALA)
CODON 198 ATT (ILE) ATC (ILE)
CODON 205 TCT (SER) TCC (SER)
CODON 206 GGC (GLY) AGC (SER)
FiGURe 2 | MICA gene exon–intron organization. The MICA gene has five introns and six exons (image by Matilde Risti).
(Continued)
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MICA Polymorphism and -129Met/val 
Dimorphism
Bahram et  al. (3) first described MICA*01 to MICA*05 alleles 
with a total of 18 nucleotide substitutions resulting in 14 amino 
acid changes in the final polypeptide. Fodil et al. (7) described 
the alleles, MICA*06 to MICA*16, with nine nucleotide substitu-
tions and eight amino acids changes. One year later, Mizuki et al. 
(18) showed a variable number of trinucleotide GCT repeats that 
encode 4, 5, 6, 7, 9, or 10 alanine (A, Ala). The short tandem 
repeats or microsatellite alleles were labeled as A4, A5, A6, A7, A8, 
A9, and A10. There is also an A5.1 allele that contains five triplet 
repeats of GCT plus an additional guanine nucleotide insertion 
(GGCT). This insertion causes a frameshift mutation leading to 
a premature intradomain stop codon within the transmembrane 
region, which deletes the MICA cytoplasmic tail. The A4, A5, A6, 
A7, A8, A9, A10, and A5.1 sizes are, respectively, 179, 182, 185, 
194, and 183 bp (18–20). At the time of writing (October 2016) 
hla.alleles.org3 reports 105 MICA alleles, 2 of which considered 
null, result in 82 different MICA proteins. All MICA alleles from 
*001 to *087 producing different proteins and their nucleotides 
variations on exons 2–6 are shown in Table 1.
Several studies have documented MICA allele frequencies 
within different populations (Figure 3), and the frequency dis-
tribution varies between them. For example, the same group of 
three alleles (MICA*008, MICA*002, and MICA*004) accounts 
for more than 50% of the allele frequencies commonly found 
in several Caucasoid populations (21–24) but at the same time 
MICA*027’s frequency is extremely different in a comparison 
between the South American Indian and Caucasoid populations 
(25). Single high-frequency MICA alleles are each associated 
with more than one different HLA-B allele, but this pattern is not 
reciprocal. Most specific HLA-B alleles, including B*07:02 and 
B*08:01 variations, are usually linked to a single MICA allele. This 
pattern suggests that the MICA alleles had an earlier origin than 
major branches of HLA-B alleles (26).
The evolutionary history of HLA-B alleles is recognizable in 
the linkage relationship between HLA-B and MICA genes. The 
high degree of sequence similarity between three HLA alleles 
(B*35, B*53, and B*58) indicates that they were all generated 
from the same progenitor allele, and the observation that glob-
ally they are all linked to the MICA*002 allele further supports 
3 http://hla.alleles.org/nomenclature/stats.html.
eXON 4 α3
CODON 208 TAT (TYR) TGT (CYS)
CODON 210 TGG (TRP) CGG (ARG)
CODON 213 ACA (THR) ATA (ILE)
CODON 215 AGC (SER) ACC (THR)
CODON 221 GTA (VAL) CTA (LEU)
CODON 230 TGG (TRP) TCG (SER)
CODON 244 TGG (TRP) TGA (Stop)
CODON 247 AAC (THR) ACT (THR)
CODON 250 TGC (CYS) CGC (ARG)
CODON 251 CAA (GLN) CGA (ARG)
CODON 253 GAG (GLU) AAG (LYS)
CODON 254 GAG (GLU) AAG (LYS)
CODON 256 AAG (ARG) AGT (SER)
AAG (LYS)
CODON 265 GGG (GLY) AGG (ARG)
CODON 268 AGC (SER) GGC (GLY)
CODON 269 ACT (THR) ATT (ILE)
CODON 271 CCT (PRO) GCT (ALA)
eXON 5 TM
CODON 295 CGT (ALA) GCGT
CODON 304 TAT (TYR) TAC (TYR)
CODON 306 CGT (ARG) TGT (CYS)
eXON 6
CODON 350 GAT (ASP) GCT (ALA)
CODON 354 ACT (THR) GCT (ALA)
CODON 359 GGC (GLY) GGT (GLY)
CODON 360 GCC (ALA) ACC(THR)
Codons are shown in the first column. The second column shows the triplets and their 
corresponding amino acids in the consensus sequence (MICA*001). The third column 
lists that triplet’s possible variations in other alleles compared with the consensus 
sequence. Amino acid substitutions in MICA on the three external protein domains 
(exons 2–4), on the transmembrane domain TM (exon 5) and carboxy-terminal 
cytoplasmic tail (exon 6). The G nucleotide insertion is represented in red in the exon 
5 TM.
TAbLe 1 | Continued
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this conclusion. Specific MICA alleles also tend to associate with 
serological HLA-B groups. A rare exception can be found in 
B*44, whose two subgroups B*44:02 and B*44:03 have exclusive 
associations with MICA*008 and MICA*004 (26).
The MICA-129Val/Met dimorphism, caused by an SNP 
(rs1051792) at nucleotide position 454 (G>A) of the MICA gene is 
of particular interest. The substitution of valine (Val) for methio-
nine (Met) at position 129 in the α2 domain of the MICA protein 
has been reported to affect NKG2D binding avidity (36–40). This 
dimorphism divides the MICA alleles into two groups (Table 2). 
In 2015, it has been observed that MICA-129Met alelles increased 
the risk of experiencing acute graft-versus-host disease. This 
effect could be the consequence on NKG2D signaling by MICA-
129Met variant (40). In addition to this, it has been shown that the 
MICA-129 dimorphism may directly affect plasma membrane 
expression and shedding of MICA, and these functional effects 
might contribute to the numerous disease associations (41).
MiCA Molecule
MICA is a highly glycosylated membrane-anchored cell surface 
protein composed of 383 amino acids (12). Unglycosylated MICA 
appeared less stable than those incorporating glycosylated MICA 
(36). Its expression has been reported on the surface of different 
cells and resembles the domain organization (Figure 4) of the α 
chain of MHC class I molecules (16, 42). MICA α chain does not 
bind β2-microglobulin and is independent of any transporter-
associated protein. Attempts to identify peptides bound to MICA 
have been unsuccessful (10, 12). The crystal structure of MICA 
shows four distinct α helices arranged in an eight-stranded 
antiparallel β sheet. These helices in MICA roughly correspond to 
the two helices that define the peptide-binding groove in peptide-
binding MHC class I proteins and homologs (42).
MICA is generally concentrated in lipid rafts and is S-acylated, 
similar to other lipid rafts-associated proteins. In vitro mutation 
of the S-acylation site, replacing a cysteine residue with a stop 
codon at aminoacid position 39, yields a truncated form of 
MICA, unable to activate NK cells (43).
The MICA molecule interacts with NK cells, γδ T cells, and αβ 
CD8+ T cells, which express NKG2D, a common activating NK 
cell receptor (4, 10, 44). NKG2D recognizes the human MICA 
protein in conjunction with a transmembrane signaling adaptor 
protein, DNAX-activation protein (DAP10) (4, 10).
It is noteworthy that the MICA molecule can also be recog-
nized by γδ  T cells with the TCR variable region Vδ1 (4, 45–47).
Both types of receptors, Vδ1TCR and NKG2D, can simultane-
ously recognize and bind to MICA on a Vδ1 cell surface. There 
is close association between the tissue distribution of Vδ1 cells 
and the physiological expression of MICA, as MICA affects Vδ1 
cell lineage development (46). In Vδ1 γδT cells, the strength of the 
binding between TCR and MICA is weaker than that between 
NKG2D and MICA. Although weak, TCR:MICA complexes 
show unusual stability after they are formed, with long half-lives. 
TCR and NKG2D receptors compete for binding to MIC ligands, 
and it has been suggested that initial interactions at the point 
of contact may be dominated by NKG2D:MIC binding events, 
which then give way to longer-lived γδ TCR:MIC complexes (47).
Conclusions on MiCA
The MICA gene is polymorphic, and it is in linkage disequi-
librium with HLA-B genes. The MICA protein is expressed on 
the cell surface, and it is possibly the proteolytic cleavage of the 
α3 domain which in turn releases soluble MICA (sMICA). The 
MICA molecule does not present a peptide in its groove and can 
interact with the NKG2D receptor, which is the focus of the fol-
lowing paragraphs.
NKG2D OR KILLER CELL LECTIN-LIKE 
RECEPTOR K1 (KLRK1) GeNe: 
STRUCTURe, POLYMORPHiSMS, AND 
FUNCTiON
NKG2D gene, also known as KLRK1, is located in the natural killer 
complex (NKC) on chromosome 12 (42, 48, 49). Human NKG2D 
(Figure 5) has 10 exons (50). Exons 2–4 encode the intracellular/
transmembrane domain; exons 5–8 encode the ligand-binding 
ectodomain, which is a membrane-bound domain protruding 
into extracellular space (50, 51). NKG2D has a low number of 
nucleotide variations (48). NKG2D appears to be conserved 
FiGURe 4 | MiCA molecule. Exon 1 encodes one leader peptide, exons 
2–4 encode three extracellular globular domains, exon 5 encodes one 
transmembrane domain, and exon 6 encodes a cytoplasmic tail (image by 
Matilde Risti).
TAbLe 2 | Dimorphism 129 val/Met divides MICA alleles into two groups.
Dimorphism 129 val/met divides MICA alleles in two groups
ATG (Met) GTG (val)
MICA*001, *002, *007, *011, *012, *014, *015, 
*017, *018, *020, *023, *025, *026, *029, *030, 
*031, *032, *034, *035, *036, *037, *038, *039, 
*040, *041, *042, *043, *045, *046, *047, *050, 
*051, *052, *055, *059, *060, *061, *068, *072, 
*075, *078, *079, *081, *083, *084, *086
MICA*004, *005, *006, *008, 
*009, *010, *013, *016, *019, 
*022, *024, *027, *028, *033, 
*044, *048, *049, *053, *054, 
*056, *057, *058, *062, *063, 
*064, *065, *066, *067, *069, 
*070, *073, *074, *076, *077, 
*080, *082, *085, *087
The most frequent alleles present in Figure 3 are shown in bold. The MICA alleles 
shown are from MICA*001 to MICA*087.4 “MICA*003:01” label has never been 
assigned to any sequence. MICA*021 sequence was renamed MICA*012:03 in August 
2007. The sequence originally labeled MICA*071 was proven to contain errors and to 
be identical to MICA*017 (March 2013) (see text footnote 3).
4 http://hla.alleles.org/alleles/classo.html.
FiGURe 3 | Frequencies (%) of common MICA alleles within 12 populations. The allele frequencies of nine MICA alleles are shown for 12 populations: 
Caucasoid (21–23), Korean (19), North-Eastern Thai (27), Japanese (13, 28), African-American (21, 29), South American Indian (25), Moroccan (30), Turkish (31), 
Brazilian (24, 32), Chinese Mongolian (33), and Chinese Tujia (34, 35) (image by Matilde Risti).
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during evolution, with orthologs of KLRK1 are present in the 
genome of all mammals, as well as in marsupials (4, 52).
Human NKG2D is expressed from at least three distinct alleles, 
and several gene transcription isoforms have been described, 
including an alternatively spliced variant that introduces a non-
sense mutation resulting in a protein isoform that lacks the entire 
extracellular ligand-binding domain (53).
Hayashi et  al. (54) evaluated the SNPs in the NKC gene 
region. They selected 20 SNPs with a >10% higher frequency in 
Caucasoid or Japanese populations (Table 3); these SNPs covered 
CD94, NKG2D, NKG2F, NKG2E, NKG2A, and Ly49 genes. They 
selected 8 out of the 20 SNPs that were closely associated with 
natural cytotoxic activity, having P values <0.001. All these SNPs 
are located in the NKG2D gene region, except for rs1983526 that 
is located in the promoter region of the NKG2A gene. These eight 
SNPs were split into two groups: group 1 (rs1049174, rs2617160, 
rs2617170, rs2617171, and rs1983526) and group 2 (rs2255336, 
rs2246809, and rs2617169). All the SNP combinations of group 1/
group 1 and group 2/group 2 revealed a strong linkage disequilib-
rium, with r2 values >0.9, whereas group 1/group 2 combinations 
showed much weaker linkage disequilibrium, with r2 values <0.5. 
This indicates that the five group 1 and three group 2 SNPs belong 
to two different haplotype blocks (NKG2D hb-1 and hb-2), each 
of which generates two major haplotypes associated with low 
TAbLe 3 | 20 SNPs selected by Hayashi et al. in their study (54).
SNP iD variation SNP iD variation NKG2D hb-1 Low High
rs3759272 G>T rs2617170 T>C rs1049174 C G
rs2537752 T>A rs2617171 C>G rs2617170 C T
rs1049174 G>C rs1971939 C>G rs2617171 C G
rs2255336 A>G rs1915319 A>G rs1983526 C G
rs2294148 G>A rs4763525 G>A rs2617160 T A
rs2049796 A>C rs3003 C>T NKG2D hb-2 Low High
rs2617160 A>T rs1983526 C>G rs2255336 G A
rs7972757 A>G rs10772285 G>C rs2246809 G A
rs2246809 A>G rs1915325 G>A rs2617169 T A
rs2617169 T>A rs2607893 C>T
Blue fields belong to group 1 and green ones represent group 2. Each of the different 
haplotype blocks (NKG2D hb-1 and hb-2) is split in low and high natural cytotoxic 
activity haplotypes. hb-1 and hb-2 may be successfully predicted knowing only 
rs1049174 (in bold).
FiGURe 5 | NKG2D gene exon–intron organization. The NKG2D gene has 10 exons and 9 introns (image by Matilde Risti).
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(LNK) and high (HNK) natural cytotoxic activity phenotypes 
(Table 3) (54).
A separate study on a European population confirmed that 
the NKG2D region haplotype associated with increased cancer 
susceptibility in the Japanese population also exists in Europeans 
at similar frequency. Therefore, the conclusions of the original 
study may also be applicable to this population (55).
NKG2D: HNK1 and LNK1 Haploblocks
Several studies have demonstrated that high and low natural 
cytotoxic activity haplotype alleles (HNK1 or LNK1) belonging to 
NKG2D haplotype blocks 1 (hb-1) may be successfully predicted 
by only a single SNP (dbSNP: rs1049174) (54, 56, 57).
A study on Japanese individuals demonstrated that the HNK1 
haplotype is associated with a greater activity of NK cells in the 
peripheral blood and a lower prevalence of cancers originating 
from epithelial cells (58). Espinoza et al. showed an association 
between the NKG2D-HNK1 haplotype (haplotype frequency, 
61%) in bone marrow donors and a significantly reduced trans-
plant-related mortality and better overall survival for unrelated 
donors of HLA-matched myeloablative bone marrow recipients 
with standard-risk disease (58).
The rs1049174 distribution for 25 populations (Figure  6) is 
reported on the 1,000 genomes website.5 HNK is reported to be 
associated with the rs1049174 (G) allele, and LNK with rs1049174 
(C) (54, 56).
NKG2D Protein
The NKG2D is a member of a C-type lectin-like family recep-
tor called CD94/NKG2 (42). Despite its inclusion in the NKG2 
family, NKG2D displays only limited sequence similarity to other 
members of the NKG2 family of NK cell surface receptors (NCRs) 
and CD94 and forms homodimers, rather than heterodimers, 
with CD94, as do other NKG2 NCRs (42).
Natural killer group 2 member D is a transmembrane-
anchored receptor expressed as a disulfide-linked homodimer on 
the cell surface, with a molecular weight of ~42 kDa (42).
In humans, each NKG2D homodimer (Figure 7) associates 
with two DAP10 homodimers to form a hexameric structure 
(59), which can signal by recruitment of phosphatidylinositol 
3-kinase (36).
Human NKG2DLs are MICA and MICB, and a group of 
glycosylphosphatidylinositol-bound surface molecules including 
UL16 binding protein(ULBP)-1, -2, -3, and -4 (6), RAET1G (or 
ULBP5), and RAET1L (or ULBP6) (60), which share about 25% 
identical amino acids in their α1α2 domains that are variably 
scattered throughout the aligned sequences without discernible 
patterns of sequence conservation (36).
Signals triggered by the NKG2D receptor are transmitted 
through the associated DAP10 dimer (Figure  7) (59) because 
NKG2D lacks a tyrosine-based inhibitory motif in its cytoplasmic 
tail (4, 61).
Natural killer group 2 member D is expressed by all human 
NK cells, γδ T lymphocytes, αβ CD8+ T lymphocytes (6), 
interferon-producing killer DC (62), invariant NKT cells cells, 
and a small subset of effector or memory CD4+ T cells (4, 52, 
63). Expression of NKG2D on NK cells and CD8+ T cells can 
be modulated by cytokines due to their effects on transcription 
and posttranscriptional processing of NKG2D and DAP10. In 
5 http://browser.1000genomes.org/Homo_sapiens/Variation/Population?db=cor
e;r=12:10524865-10525865;v=rs1049174;vdb=variation;vf=750969.
FiGURe 7 | NKG2D and DAP10. Representation of the hexametric 
structure formed by one NKG2D and two DAP10 homodimers (image by 
Matilde Risti).
FiGURe 6 | 1000 Genomes frequency for the G>C alleles (NKG2D hb-1) (see Footnote 5). The population represented are African Caribbean in Barbados 
(ACB), African Ancestry in Southwest US (ASW), Esan in Nigeria (ESAN), Luhya in Webuyu Kenya (LWK), Mandinka in Degambia (MAG), Mende in Sierra Leone 
(MSL), Yoruba in Ibadan Nigeria (YRI), Utah Residence with Northern and Western European Ancestry (CEU), Finnish in Finland (FIN), British in England and Scotland 
(BGR), Iberian populations in Spain (IBS), Toscani in Italy (TSI), Chinese Dai in Xishuangbanna, China (CDX), Han Chinese in Bejing, China (CSH), Japanese in Tokyo, 
Japan (JPT), Kinh in Ho Chi Minh City Vietnam (KHV), Bengali in Bangladesh (BEB), Gujarat Indian in Houston Texas (GIH), Indian Telegu in the UK (ITU), Punjabi in 
Lahore Pakistan (PJL), Srilankan Tamil in the UK (STU), Colombian in Medellin Colombia (CLM), Mexican Ancestry in Los Angeles, California, USA (MXL), Peruvian in 
Lima Peru (PEL), and Puerto Rican in Puerto Rico (PUR).
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humans, IL-2, IL-7, IL-12 (64), IL-15, and IFN-α (65) upregulate 
NKG2D expression, whereas TGFβ (65–67), IFNβ1 (68), and 
IL-21 (69), IL-4, IL-12, and IFNγ (65) downmodulate NKG2D. 
This downregulation can also be attributed to the overexposure 
to soluble or membrane-bound NKG2DLs, which promote the 
internalization and subsequent degradation of the receptor or 
catabolites produced on macrophage activation [reactive oxygen 
species (ROS) and l-kynurenine] (65). This is a possible explana-
tion of the mechanism of oxidative stress, which is a common 
feature of chronic renal failure. ROS trigger the upregulation of 
MICA and downregulation of NKG2D in NK cells in vitro (70). 
DAP10 availability is also a decisive factor in NKG2D surface 
expression, and miRNAs can downregulate NKG2D expression 
in NK cells, reducing its cytotoxic effect (65).
Fernandez-Sanchez et al. (65) have shown for the first time that 
epigenetic mechanisms are involved in the regulation of NKG2D 
expression. They analyzed the region around the translation 
initiation site of the NKG2D gene (which included 11 CpG sites 
between −992 and +263 positions), and they found the greatest 
differences in DNA methylation patterns between the positions 
−992 and −255. These CpGs were highly methylated in Jurkat, 
HUT78 cell lines and CD4+ T cells, partially methylated in CD8+ 
T lymphocytes and NK cells, and fully demethylated in NK cells 
lines. They discovered that the acetylation of histone H3 lysine 
9 (H3K9) is important for correct NKG2D expression in NK 
and CD8+ T cells, while DNA demethylation may be associated 
with an increased expression of NKG2D in CD4+ T cells. The 
DNA methylation profile of DAP10 gene was also analyzed, but 
no differences were found. CD4+ T lymphocytes and T cell lines 
(Jurkat and HUT78) had a DNA methylation; instead NKG2D-
positive cells (CD8+ T lymphocytes, NK cells, and NKL cell line) 
had an unmethylated NKG2D gene and high levels of histone H3 
lysine 9 acetylation (H3K9Ac). It was observed that the histone 
acetyltransferase inhibitor, curcumin, reduced H3K9Ac levels in 
the NKG2D gene, downregulated NKG2D transcription, and led 
to a marked reduction in the NKG2D-mediated lytic capacity of 
NK cell lines (65).
Another interesting study by Karimi et  al. (71) of human 
primary NK and CD8+ T cells discovered a novel splice variant 
of human NKG2D that encodes a truncated receptor lacking 
the ligand-binding ectodomain (NKG2DTR). Overexpression 
of this truncated isoform severely attenuated cell killing and 
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IFNγ release mediated by full-length NKG2D (NKG2DFL). 
A specific knockdown of an NKG2DTR isoform enhanced 
NKG2D-mediated cytotoxicity, suggesting that NKG2DTR is a 
negative regulator of NKG2DFL. At the biochemical level, it was 
demonstrated that NKG2DTR bound to DAP10 and interfered 
with the DAP10–NKG2DFL interaction. In addition, NKG2DTR 
formed heterodimers with NKG2DFL and negatively modulated 
NKG2DFL preventing its surface expression. Therefore, NKG2DTR 
constitutes a mechanism for regulation of NKG2D-mediated 
function in human CD8+ T cells and NK cells (71).
Unlike CD8+ T cells, TCR-mediated activation is not sufficient 
to induce NKG2D expression on CD4+ T cells, and the factors 
responsible for induction of NKG2D on CD4+ T cells are still 
unknown (71).
Saez-Borderias et  al. (63) provided the first evidence that a 
subset of human cytomegalovirus (HCMV)-specific CD4+ T 
cells displays NKG2D. Their data suggest that CD4+NKG2D+ 
cells expanding in HCMV-stimulated cultures correspond to 
virus-specific memory T cells that have acquired NKG2D while 
losing CD28 (63).
Conclusions on NKG2D
The NKG2D gene can be split into two haploblocks: HNK1 and 
LNK1 (high and low cytotoxic activity related). The NKG2D pro-
tein is a homodimer associated with two DAP10 molecules and 
can interact with MICA. In NK cells, the NKG2D protein is an 
activation receptor which is able by itself to trigger cytotoxicity. 
This is the main reason why it is interesting to study the rela-
tionship between MICA and NKG2D in depth in the following 
paragraphs.
MiCA LiGAND AND iTS ReCePTOR 
NKG2D: FUNCTiONAL iNTeRACTiONS
The crystal structure of the MICA–NKG2D complex shows that 
NKG2D binds to one MICA molecule as a homodimer. One of 
the NKG2D molecules binds mostly to the α1 domain of MICA, 
while the other binds mostly to the α2 domain (6). The contact 
between these two molecules creates a small pocket (roughly 6 Å 
wide × 6 Å thick × 14 Å long) (42).
The NKG2D homodimer overlays MICA diagonally in way 
that resembles αβTCR overlaying MHC I molecules. The central 
section of the MICA α2 domain is disordered when MICA is 
crystallized in isolated form, but it becomes ordered when MICA 
is bound to NKG2D and forms part of the interface between the 
two molecules (6).
MICA glycosylation was not essential, but it enhanced com-
plex formation with NKG2D. Likewise, the glycosylation state of 
NKG2D had no substantial effect on complex formation (36).
MICA–NKG2D is considered a versatile ligand–receptor 
pair. As a matter of fact, NKG2D can act as a primary receptor 
or costimulatory molecule during infections, autoimmunity, or 
antitumor immune responses (6). For example, it has been shown 
that endothelial MICA triggeres an activating signal in allogeneic 
polyclonal NK cells through the immunoreceptor NKG2D, which 
may have account for a significant part in EC lysis by allogeneic 
NK cells. In vitro coculture assays show that interaction of 
endothelial MICA with NKG2D provides an immune suppressive 
pathway by downregulating NKG2D on the NK cell surface (14).
Boukouaci et al. (72) suggested that endocytosis of the NKG2D 
receptor, upon binding to sMICA, is considerably more rapid than 
the replenishment of cell surface NKG2D by de novo synthesis. 
The same authors also found that sMICA down regulates NKG2D 
receptor expression on CD8+ T cells. sMICA upregulates the IFNγ 
production only by cytokines-activated NK cells, while it has no 
effect on non-activated cells. The researchers demonstrated that 
sMICA upregulates IFNγ expression by IL-12/IL-18-activated 
CD3 CD56+ NK cells, demonstrating the pro-inflammatory 
effect of sMICA (72). A study with a mouse model found that 
Lewis rat hearts transplanted into BALB/c mice developed typical 
acute rejection (AR) in 6 days. The severity of xenograft rejection 
increased with time, from 2 to 6 days. Also increasing over time, 
the MICA protein and MICA mRNA reached their highest value 
after 6 h. The prevalence of anti-MICA was significantly higher 
among mice with severe AR. However, sMICA was significantly 
increased during AR at 2 h, then gradually decreased, and reach-
ing its lowest value after 6 h (73).
MiCA–NKG2D AND KiDNeY TRANSPLANT
In the last few decades, the role of MICA and NKG2D in kidney 
transplants has emerged (Table  4). The involvement of NK 
cells was discovered in 1995 when some indirect evidence was 
reported during rejection of kidney transplants. Accumulation 
of CD56+ NK cells expressing granzyme in kidney biopsies of 
patients undergoing AR suggested a role of their cytolytic activity 
in kidney-allograft rejection (74). Over the years, the association 
between NK cells and the mechanisms of microcirculation injury 
during antibody-mediated rejection (AMR) in kidney transplants 
has become increasingly evident. The researchers proposed 
that donor-specific antibodies (DSA) were able to bind to the 
endothelium and to recruit NK cells that produce IFNγ and trig-
ger antibody (Ab)-dependent cellular cytotoxicity (75).
NK Cells and Kidney Damage in Mice and 
Cell Lines
Natural killer group 2 member D-ligand engagement delivers a 
strong dominant activating signal that overrides the inhibitory 
signal delivered by self-MHC class I, thus activating NKG2D-
expressing cells, resulting in innate and adaptive immunity 
activation (113).
Zhang et al. (116) reported a study on ischemia/reperfusion 
injury (IRI) on mice and discovered the capacity of NK cells 
to injure renal tubular epithelial cells in vitro. In vivo data sup-
ported the hypothesis that NK cells interact with tubular epithelia 
through NKG2D/Rae-1 interaction to mediate kidney damage 
following IRI.
Luo et al. (89) performed an in vitro study on human renal 
proximal tubular epithelial cell line (HK-2). They discovered that 
hypoxia-inducible factor-1-α (HIF-1α) plays a very important 
role in upregulating MICA expression and enhancing NK cell 
cytotoxicity toward target cells during hypoxia/reoxygenation in 
HK-2 cells. HIF is a heterodimer consisting of an α-subunit (HIF-
1α) and a β-subunit (HIF-1β), the HIF-1β protein is constitutively 
TAbLe 4 | Relevant published work regarding NKG2D, MiCA, and kidney transplants.
Reference Summary MiCA biomarker
Relevant published works regarding MiCA and transplants
Zwirner et al. (76) Several patients had specific antibodies (Abs) against MICA. Most of them were detected in serum samples 
collected at different times after organ rejection
Yes
Hankey et al. (77) MHC class I chain-related expression was documented in allografted kidneys and pancreas. Expression of MICB 
was observed in epithelial cells in allografted kidney and pancreas that showed histologic evidence of rejection and/
or cellular injury
Yes
Opelz (78) This work showed that non-HLA immunity contributed substantially to long-term kidney transplant failure. The 
targets for Abs causing late rejections could be called minor histocompatibility antigens
Yes
Mizutani et al. (79) Patients who rejected transplants had anti-HLA and anti-MICA Abs more frequently than those with functioning 
grafts. These Abs found in the peripheral circulation were not necessarily donor-specific, but their association with 
failure was consistent with a causality hypothesis
Yes
Amezaga et al. (80) Anti-MICA Abs were not detected pretransplant nor posttransplant in patients receiving a compatible graft. Anti-
MICA Abs were detected posttransplant acute antibody-mediated rejection in patients receiving an incompatible 
graft
Yes
Mizutani et al. (81) Anti-HLA and anti-MICA Abs were present independently on a more frequent basis in patients with failed grafts than 
those with functioning grafts
Yes
Panigrahi et al. (82) Patients who developed both anti-HLA and anti-MICA Abs rejected their grafts more frequently than those having 
either of these Abs
Yes
Zou et al. (83) Pre-sensitization of kidney transplant recipients against MICA antigens had been associated with an increased 
frequency of graft loss and might contribute to allograft loss among recipients who were well matched for HLA
Yes
Seiler et al. (62) Unlike previous reports, in this work the researchers could not detect elevated MICA mRNA levels in kidney biopsies 
derived from patients undergoing acute rejection (AR) or chronic allograft nephropathy. In contrast, they observed 
a strong NKG2D mRNA induction during renal-allograft rejection, which was verified by immunohistology in kidney 
biopsies
No
Suarez-Alvarez et al. 
(84)
Anti-MICA Abs were detected in 17.6% of the patients and correlated with the development of AR. The presence of 
anti-MICA Abs could be an important marker for diagnosis because of their contribution to the outcome of the graft, 
regardless of presence of anti-HLA Abs
Yes
Alvarez-Marquez et al. 
(85)
At the time of the biopsy, 21% patients had only anti-HLA I Abs, 15.8% had anti-GSTT1 Abs, 10.5% had anti-HLA II 
Abs, and 10.5% had anti-MICA Abs. Besides anti-HLA Abs, donor-specific Abs against MICA and GSTT1 antigens 
could be responsible for the occurrence of Ab-mediated kidney graft rejection
Yes
Racca et al. (86) This work did not show a correlation between MICA expression and renal graft state. The state of kidney allograft 
could be measured by using HLA-G1 isoforms, but not MICA mRNA levels, as markers
No
Lemy et al. (87) The comparison between anti-MICA Abs+ and anti-MICA Abs− patients showed that the incidence of AR episodes 
during the first year was similar in both groups. MICA Abs did not adversely affect renal graft outcomes
No
Li et al. (88) Anti-MICA Abs were detected in 11 of the 15 transplant patients, irrespective of interval acute graft rejection. Also, 
integrative genomics predicted localization of the MICA antigen on the glomerulus in the kidney. MICA localization 
may explain both immunoregulatory and pathogenic roles for MICA after transplantation
Yes
Luo et al. (89) HIF-1α plays a very important role in upregulating MICA expression and enhancing natural killer (NK) cell cytotoxicity 
toward target cells during hypoxia/reoxygenation in HK-2 cells. Their results demonstrated that hypoxia/
reoxygenation-promoted MICA expression on HK-2 cells is through a HIF-1 pathway
Yes
Cox et al. (90) Anti-MICA and anti-HLA Abs significantly associated with AR and anti-MICA donor-specific antibodies (DSA) and 
anti-HLA DSA correlated with decreased graft function by univariate and multivariate analysis. The researchers 
concluded that mismatching for MICA epitopes in renal transplantation is a mechanism leading to production of 
MICA Abs that associate with AR and graft dysfunction
Yes
Narayan et al. (91) Case report: this case demonstrated that donor-specific anti-MICA Abs could be associated with both acute 
antibody-mediated rejection (AMR) and type IIA acute cellular rejection and emphasized the necessity of treating 
both humoral and cellular components of the rejection
Yes
Yao et al. (92) The authors proved that Anti-MICA Abs+ rate was significantly higher in sensitized recipients and it had significant 
effect on the recovery of allograft function in early postoperative period. Protein A immunoadsorption plays an 
important role in decreasing preexisting Abs, especially the anti-MICA Abs
Yes
(Continued )
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Reference Summary MiCA biomarker
Zhang et al. (93) Anti-MICA Abs were present in 28.9% of patients and they were associated with renal-allograft deterioration. The 
researchers concluded that, besides anti-HLA Abs, the presence of posttransplant anti-MICA Abs was associated 
with poor graft outcome and increased the risk of graft failure
Yes
Lemy et al. (94) Anti-MICA Abs+ patients were more frequently anti-HLA Abs sensitized and regrafted. Four-year death-censored 
graft survival was not different between MICA+ and MICA− patients. These data did not support an independent 
pathogenic role for MICA in long-term renal graft injury
No
Li et al. (95) The levels of the peak mean fluorescence intensity of MICA Abs in patients with impaired renal function were 
significantly higher than those in normal renal function controls. They also concluded that some MICA Abs might be 
more important than others in mediating graft rejection
Yes
Seyhun et al. (96) Anti-HLA class II and anti-MICA Abs+ were only important predictors of graft failure when present together with 
anti-HLA I Abs+. Patients who developed anti-HLA Abs alone or both anti-HLA Abs and anti-MICA Abs rejected their 
grafts more frequently than Abs− recipients
Yes
Rodriguez Ferrero et al. 
(97)
They compared patients with versus without preformed circulating antibodies (circulating anti-MICA Abs and anti-
HLA Abs), and they did not observe a significant difference in graft survival or renal function at 3-month follow-up
No
Solgi et al. (98) This research supported the idea that monitoring of anti-HLA and anti-MICA Abs as well as soluble CD30 levels 
early after transplant had predictive value for early and late allograft dysfunctions and the presence of these factors 
was detrimental to graft function and survival
Yes
Akgul et al. (99) In this study, the scientist observed the role of anti-HLA II Abs in the development of chronic active AMR and 
in long-term allograft survival. It is observed that anti-MICA and anti-GSTT1 Abs showed no effect on rejection 
mechanisms
No
Chaudhuri et al. (100) Anti-MICA and anti-HLA Abs appeared in approximately 25% of unsensitized pediatric patients, placing them at 
greater risk for acute and chronic rejection with accelerated loss of graft function
Yes
Ding et al. (101) When comparing patients with acute graft rejection against recipients with stable renal functions, the researchers 
highlighted a significantly higher positivity rate of anti-MICA Abs. The status of anti-MICA Abs can predict the 
occurrence and treatment outcomes of AR, and affect the long-term survival of the renal grafts
Yes
He et al. (102) By following transplantation recipients during follow-ups, anti-HLA and anti-MICA Abs expression was proven to 
have a predictive value for early and late allograft dysfunction. The presence of donor-specific Ab is detrimental to 
graft function and graft survival
Yes
Jin et al. (103) They observed the prevalence of panel-reactive antibody (PRA) and anti-MICA Abs to be increased among Ptc, 
albeit not significantly different from C4d AR. These results implied that Ptc could be an early indicator of AR
Yes
Li et al. (104) CD19+ B cells and CD19+CD27+ memory B-cell subsets were detected from peripheral blood mononuclear cells 
obtained from six anti-MICA-sensitized kidney recipients. Kidney recipients had a higher percentage of CD19+CD27+ 
B cells compared with healthy controls. This study thus showed that B cells may be stimulated to secrete Abs
Yes
Sanchez-Zapardiel et al. 
(105)
The researchers detected that pretransplantation sensitization against anti-MICA and anti-HLA Abs were 
independent events. Preformed anti-MICA Abs independently increase risk for kidney rejection and enhance the 
deleterious effect of PRA+ status early after transplantation
Yes
Tonnerre et al. (106) The researcher found that individual carrying MICA A5.1/MICA A5.1 had 10-fold higher levels of MICA mRNA and 
MICA proteins at the endothelial cell surface. They also demonstrate a significant association between D/R MICA 
A5.1 mismatch and anti-MICA alloimmunization, particularly when donors carry the A5.1 mutation. They concluded 
that A5.1 mutation is an immunodominant factor and a potential risk factor for transplant survival
Yes
Zhang et al. (107) 5 years after transplantation, the frequencies of de novo anti-HLA and anti-MICA Abs were 25.8 and 12%, while 
26.5% of patients had proteinuria. All of these factors have been associated with poor graft survival
Yes
Sapak et al. (108) The researchers did not prove a complete correlation between the recipient anti-MICA Abs specificities and 
MICA antigens of the donor. They assumed that anti-MICA Ab induction occurred not only due to the allogeneic 
stimulation itself but also due to other factors that needed to be elucidated
No
Ming et al. (109) Case report: the patient’s HLA alloantibodies were not specific to the first kidney donor, but the MICA alloantibodies 
were. This indicates the importance of MICA virtual crossmatch in the process of selection for the kidney donor if 
the recipient is sensitized.
Yes
Xu et al. (110) Serum anti-HLA II Abs, anti-MICA Abs, and anti-HLA plus MICA Abs all statistically increased in renal-transplanted 
recipients
Yes
(Continued )
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Reference Summary MiCA biomarker
Cai et al. (111) Transplant recipients had Abs against denatured HLA class I, II, and MICA antigens. However, only C1q-fixing Abs 
were associated with graft failure, which was related to AMR
Yes (only for c1q-fixing 
denaturated MICA Abs)
Sanchez-Zapardiel et al. 
(112)
Occasionally, preformed anti-MICA Abs may be cytotoxic by activating and fixing complement. This could lead to a 
reduced function in early kidney grafts
Yes
Relevant published works regarding NKG2D and transplant
Feng et al. (113) Ischemia/reperfusion injury (IRI) caused mRNA expression of Rae-1 and protein expression of Rae-1 in ischemic 
kidneys. This study suggested that the expression of the NKG2D ligand, Rae-1, may play a potential role in innate 
immunity associated with IRI
Zheng et al. (114) The absence of enhancement of NKG2D expression in the kidney in AN in immunodeficient mice suggested that the 
populations expressing NKG2D were likely to be CD8 or γδ T cells, which were not present in the immunodeficient 
mice, rather than macrophages, which were present and activated in both models of AN
Seiler et al. (62) Unlike previous reports, in this paper, the researchers could not detect elevated MICA mRNA levels in kidney 
biopsies derived from patients undergoing AR or chronic allograft nephropathy. In contrast, they observed a strong 
mRNA induction of NKG2D during renal-allograft rejection, which could be verified by immunohistology in kidney 
biopsies
Hadaya et al. (115) The results of this paper have shown an expansion of the NKG2D+ NK cell population during acute cytomegalovirus 
(CMV) infection (after kidney transplantation), which decreased over time to a level very similar to that of the control 
group. This suggests that the NKG2D receptor could play a similar role in NK and CD4+ T cells
Zhang et al. (116) In this study, the researchers demonstrated for the first time that NK cells could induce kidney TEC death in vitro 
and that NKG2D and Rae-1 interactions played a critical role in this killing in mice
Shabir et al. (117) Cytotoxic CD4+ CD28null cell is an important biomarker for and potential mediator of adverse events after kidney 
transplantation. NKG2D represents an integral component of CMV immunosurveillance and immunoevasion and 
was upregulated on CD4+ CD27− CD28null cells isolated from patients of this study. The researchers proposed it as 
an important component of the cytotoxic effects (either protective or pathogenic) of these cells
“Yes” and “No” labels have been used if, in the studies analyzed, MICA has been valued as a possible biomarker (“Yes”) or not (“No”).
TAbLe 4 | Continued
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present, while HIF-1α has a unique O2-dependent degradation 
domain, which leads to its degradation under normoxia condi-
tions. The authors speculate that HIF-1α upregulates the surface 
expression of MICA on grafts during renal IRI, causing NK cells 
cytotoxicity against the organ (89).
Possible Causes of end-stage Renal 
Disease
A 2009 study of the possible causes of end-stage renal disease 
(ESRD) (70), while note directly related to kidney transplants, 
inevitably reported findings of consequences for kidney trans-
plantation. Peraldi et al. evaluated seven patients with ESRD that 
were treated with peritoneal dialysis, and not with the hemodi-
alysis procedure; NKG2D expression on NK cells was signifi-
cantly decreased in these patients compared to healthy donors, 
indicating that reduction in NKG2D expression was independent 
of the dialysis procedure and linked with chronic renal failure. 
The authors also discovered that oxidative stress in presence of 
increased ROS production is one of the most significant conse-
quences of chronic renal failure, alone or in concert with other 
mediators, and it seems to decrease the NKG2D levels on NK cells 
in ESRD and to favor the upregulation of MICA expression (70).
Anti-MiCA Abs and Rejection
Some mechanisms have been proposed for MIC-mediated organ 
rejection. MICA antigens expressed in the allograft could induce 
the generation of anti-MICA Abs, which in turn might injure cells 
in the presence of complement.
This section contains no works that focus solely on NKG2D 
since most of the manuscripts are almost exclusively conserved 
with anti-MICA Abs: NKG2D is often just a side note; its presence 
and the link with MICA are given.
MICA-Sensitized Kidney Recipients and Higher 
Percentage of CD19+CD27+B Cells
CD19+CD27+ B cells are the subset of memory B cells that have 
the potential ability to secrete Abs. Li et  al. (104) assessed the 
serum from 68 long-term survival kidney recipients and found 
11 subjects who were MICA positive. They analyzed six MICA-
sensitized kidney transplant recipients and six healthy volunteers 
who did not receive a transplant (control group). Healthy con-
trols had a higher percentage of CD19+CD27− in PBMCs than 
transplant patients, while the percentage of CD19+CD27+ in B 
cells was higher in transplant patients. The MICA-sensitized 
transplant patients had a significantly lower average percentage of 
CD19+ B cells in PBMC than healthy controls (3.58 ± 0.80 versus 
8.53 ± 1.04%; P < 0.01). These results suggest that CD19+CD27+ 
B cells from sensitized patients have the potential ability to secrete 
Abs. In the same study, PBMC cells were isolated and cultured and 
stimulated with different molecules [toll-like receptor-9 ligand 
ODN-2006 CpG, PMA, B-cell activating factor (BAFF), CD40 
ligand (CD40L), human recombinant IL-2 (rhuIL-2), rhuIL-10, 
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rhuIL-4, rhuIL-21, CD40L, and BAFF] including MICA antigens. 
After stimulation, B cells from healthy controls and transplant 
patients had a lower percentage of apoptosis than non-stimulated 
cells. The average percentage of apoptosis cells from transplant 
patients was significantly higher than from healthy controls, and 
the IgM production (the first Ab produced by B cells after antigen 
stimulation) was higher in stimulated B cells from transplant 
patients than from healthy controls. The authors speculate that 
the B-cell population may be compromised by the transplant 
because patients are under immunosuppressive regimens, which 
may alter the apoptosis of B stimulated cells compared with 
healthy controls. The same study also performed an in vitro study 
with drugs and found that bortezomib and mycophenolic acid 
could inhibit B-cell Ab secretion (104).
MICA Abs
Hankey et al. (77) first reported that MICA and MICB expression 
on epithelial cells in transplanted kidneys and pancreases with 
histological evidence of rejection and cellular injury played a role 
in allograft rejection. The study showed that in a healthy kidney 
there was no immunochemical evidence of MIC expression. In 
contrast, the majority of biopsies with histologic proof of rejection 
or acute tubular necrosis (ATN) showed MICA positive staining 
of the tubular epithelium in the proximal and distal tubules. For 
this reason, it was concluded that alloantibodies against MICA 
might play a role in allograft rejection.
Zwirner et  al. (76) found that several patients who had 
undergone a kidney transplant had specific Abs against MICA, 
and most of them were detected in serum samples collected at 
different times after organ rejection. However, these Abs were 
not directed against the alleles expressed by the patients, and it 
was speculated that if the presence of MICA Abs was probably 
caused by multiple blood transfusions received by the patients 
while awaiting a transplant, or resulting from a pregnancy or a 
previous transplant (76).
Lemy et  al. (87) analyzed the MICA Abs from 494 controls 
and 597 patients with chronic kidney disease. They found a three 
times higher prevalence of MICA Abs in patients with chronic 
kidney disease when compared with controls (14.9 versus 4.7%). 
Nevertheless, they speculated that even if the increase in MICA 
Abs prevalence among patients affected by chronic kidney dis-
ease was probably related to previous renal transplantation and 
transfusions. Logistic regression analysis and analysis of chronic 
kidney disease patients who have not been subjected to transfu-
sions and renal transplantations suggest that the increase of urea 
(and other nitrogenous waste) in the blood is connected to an 
increase of MICA immunization. The authors also reported that 
MICA Abs were more frequent in men than in women, despite 
pregnancy being an independent risk factor for the development 
of MICA Abs (87). This finding is in sharp contrast with other 
published work. The fact that nearly one-third of MICA chronic 
kidney disease stage V patients have never experienced any 
identifiable immunizing event indicates that there must be other 
causes for MICA sensitization. At the same time, one-fifth of the 
same patients showed the presence of autoreactive MICA IgG 
Abs, distinctly rare with respect to HLA Abs. The authors showed 
that patients with MICA Abs had a somewhat better overall graft 
survival than MICA Abs− patients. Finally, Lemy et  al. found 
in MICA Abs+ and MICA Abs− patients a similar incidence of 
AR episodes during the first year (10.2 versus 12.8%), as well as 
similar levels of proteinuria and creatinine (87).
Another study of MICA Abs screened 147 recipients with 
end-stage renal disease; 82 of these patients were Abs+ (55.8%). 
Forty patients had both anti-HLA and anti-MICA, 33 had only 
anti-HLA, and 9 only anti-MICA Abs in the posttransplant 
period. The authors found that patients who developed HLA 
alone, or both HLA and MICA Abs, rejected their grafts more 
frequently than Abs− recipients. The rates of HLA class I, class II, 
or both Abs+ were greater in the rejection patients than the non-
rejection patients (P = 0.011, 0.037, and 0.0275, respectively). So 
the authors speculated that HLA class II and MICA Abs+ were the 
only important predictors of graft failure when both of them were 
present with HLA class I Abs+ (96).
In a retrospective study, Solgi et al. (98) analyzed sera samples 
of 40 living unrelated donor kidney recipients, looking at anti-
HLA and anti-MICA Abs and the levels of soluble CD30 (sCD30) 
and sMICA. They found that patients with pre- and posttransplant 
HLA Abs had a higher incidence of AR episodes (P = 0.01 and 
P = 0.02), more graft loss (P = 0.001), and lower graft survival 
during a mean follow-up of 3 years. This group of patients also 
had higher levels of sCD30 and serum creatinine and decreased 
contents of sMICA early after transplantation, as compared to 
the patients without HLA Abs. Anti-MICA Abs were observed in 
8/40 (20%) and 5/40 (12.5%) of all patients pre- and posttrans-
plant, respectively. HLA and MICA Abs were both found in two 
out of four cases with graft loss. In a comparison of transplant 
rejecting to functioning graft groups, sCD30 levels increased at 
day 14 (P = 0.001), while sMICA levels were insignificantly lower 
in the first group (98).
Chaudhuri et  al. (100) studied the evolution of humoral 
immunity in low-risk pediatric patients during the first 2 years 
after renal transplantation. They correlated the presence of serum 
anti-HLA DSA and serum MICA Abs with clinical outcomes 
and histology (the biopsies were performed at 0, 6, 12, and 
24 months). They found anti-HLA Abs in 22% of patients, 6% 
of which were donor-specific, while 6% developed anti-MICA 
Abs. Three percent of patients developed de novo Abs to both 
HLA and MICA. The presence of de novo Abs was associated with 
significantly higher risks for AR (P = 0.02), chronic graft injury 
(P = 0.02), and decline in graft function (P = 0.02). Graft function 
was monitored by the difference between creatinine clearances. 
Anti-MICA and -HLA Abs were found in 25% of unsensitized 
pediatric patients. This was correlated with a greater risk of acute 
and chronic rejection (100).
Zhang et al. (107) associated the presence of de novo MICA 
Abs and proteinuria with graft failure, after renal transplantation. 
They investigated 275 patients without preexisting anti-HLA and 
-MICA Abs. Five years after renal transplantation, 25.8% showed 
de novo anti-HLA Abs, 12% showed de novo anti-MICA Abs, and 
26.5% proteinuria. De novo anti-HLA Abs were associated with 
increased proteinuria after transplantation (relative risk, 3.12). 
Anti-HLA Abs and proteinuria were both associated with poor 
5-year graft survival (P =  0.027 and P =  0.006, respectively). 
Patients with de novo anti-MICA Abs were also apt to have 
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proteinuria. The authors concluded that de novo anti-HLA and 
-MICA Abs and proteinuria are all associated with poor graft 
survival (107).
Pretransplant Panel-Reactive Abs and Preexistent 
Circulating Abs
Opelz (78) studied the influence of pretransplant panel-reactive 
antibody (PRA) status on the long-term outcome of kidney 
grafts from HLA-A, -B, and -DR, identical sibling donors. In 
over 10 years of follow-up, he discovered that non-HLA-directed 
immunity and Abs against HLA had a similar influence for the 
long-term results for kidney recipients with PRA. Opelz sug-
gested that the targets for Abs causing late rejections could be the 
so-called minor histocompatibility antigens (78).
Sanchez-Zapardiel et  al. (105) studied 727 transplanted 
patients and showed that the effect of anti-MICA Abs occurs 
independently of the presence of anti-HLA Abs. Pacients were 
categorized into four groups according to the presence (+) or 
absence (−) of anti-HLA and anti-MICA Abs: HLA+MICA+ 
(n  =  27); HLA−MICA− (n  =  510); HLA+MICA− (n  =  165), 
and HLA−MICA+ (n = 25). A notable difference was observed 
3  months after transplantation, when HLA−MICA+ patients 
had a graft rejection rate of 8% compared with 2% in HLA− 
MICA− patients. The patients were also grouped according to the 
presence of preexisting anti-HLA Abs, as measured by % PRA 
(PRA+ or PRA−): PRA+MICA+ (n = 7), PRA−MICA− (n = 610), 
PRA+MICA− (n = 65), and PRA−MICA+ (n = 45). The incidence 
of rejection was found to be superior in PRA+MICA− cohort 
versus PRA−MICA− patients (24 months after transplantation), 
but allograft rejection rate was the highest when comparing 
PRA+MICA+ patients with PRA−MICA− patients 3 months after 
transplantation, a finding which was repeated at 6 months (105). 
This work is of interest because it performed a comparative 
study on the effects of anti-MICA and anti-HLA Abs on kidney 
transplants.
The Rodriguez Ferrero et al.’s (97) study included 22 recipi-
ents of kidney transplantations from deceased donors, and no 
differences between patients that showed preexistent circulating 
antibodies (CA) and those that did not were reported. In regards 
to the incidence of AR episodes, the only factor associated with 
CA was re-transplantation. So the authors concluded that CA 
monitoring is important for highly sensitized renal transplants, 
but they did not observe a difference in graft survival or renal 
function in the first 3-month follow-up (97).
Cd4 Deposition and C1q-Fixing Abs
A study of patients with acute antibody-mediated rejection 
(AAMR), who had MICA*008 Ab, showed that the presence of 
anti-MICA Abs and the deposition of C4d in biopsies performed 
at the time of AAMR was associated with the detection of DSA or 
Abs against HLA (80). The observation that the control group of 
30 patients with long-term functioning grafts did not have anti-
MICA*008 Abs provided indirect evidence of the importance of 
anti-MICA Abs in chronic rejection. Furthermore, all patients 
receiving an allograft fully matched at MICA had functioning 
grafts (80). It is also important to mention that MICA Abs are 
able to activate complement in in vitro experiments (80).
Alvarez-Marquez et al. (85) selected 58 patients that under-
went a kidney biopsy because of primary non-function, delayed 
graft function or acute dysfunction of a previously functional 
graft, suspected by oliguria, increase of serum creatinine levels, 
or proteinuria. At the time of the transplant, all patients showed 
negative complement-dependent cytotoxicity crossmatches. 
Researchers demonstrated that 80% of a group of 19 patients with 
clinically evident graft dysfunction and with C4d deposition in 
kidney biopsies had Abs directed against donor-specific HLA 
class I, class II, MICA, or GSTT1 (glutathione-S-transferase T1) 
antigens (85).
In the Li et al.’s (88) study, a human ProtoArray platform was 
used to study 37 serum samples from 15 renal transplant patients 
(pediatric and young adult) with (n = 10) and without (n = 5) 
AR, and seven normal controls. To test serum Abs, they used 
a ProtoArray containing 5,056 non-redundant human proteins 
expressed in a baculovirus system, purified from insect cells 
and printed in duplicate onto a nitrocellulose-coated glass slide. 
Moreover, all patients were primary transplant recipients, and 
the biopsies were graded by the Banff classification. The authors 
found that the mean immune response signal in posttransplant 
patient serum showed an increase in anti-MICA Abs when com-
pared with healthy normal controls (n = 7), but anti-MICA Abs 
signal intensity was unrelated to the sampling time interval post-
transplantation. Mean MICA Abs signal intensity was higher in 
transplant patients with C4d+AR (121.4) versus C4d−AR (4.3), so 
a correlation between high MICA Abs levels and C4d+ graft rejec-
tion r = 0.54 (P = 0.039) was observed. On ProtoArray, each gene 
on the cDNA platform was compared between a specific kidney 
compartment versus all other compartments, by a two-unpaired 
class comparison and a multi-class comparison. The signal 
intensity of anti-MICA Abs ranked in the top 15 for glomerulus, 
so the MICA antigen was found to have a 2.7-fold higher expres-
sion in the glomerulus when compared to the other 6 normal 
kidney compartments. Cytoplasmic granular staining for MICA 
in normal and stable transplanted kidneys was observed solely in 
podocytes within glomeruli. In AR, in addition to the persisting 
glomerular staining, the infiltrating mononuclear lymphocytes 
also showed strong positive staining for MICA. So the authors 
demonstrated that Ab responses in patients are modulated by 
MICA after transplantation in patients, irrespective of graft 
rejection (88).
Another study correlates Cd4 deposition and creatinine levels. 
Ding et al. (101) evaluated serum anti-MICA Abs before and after 
kidney transplant, and they also examined PRA, serum creatinine, 
urine, graft ultrasound, lymphocyte subsets, and the pathology of 
graft biopsy. The study was split into two parts. In the first part, 
patients with AR were grouped into MICA+, MICA− (P < 0.05) 
and control groups. There were a significantly higher number 
of anti-MICA Abs positive patients with acute graft rejection 
compared with stable renal functions patients (control group).
Two to three days after the occurrence of AR, the anti-MICA 
Abs level increased gradually. Anti-rejection treatment had no 
effect on anti-MICA Abs but lowered serum creatinine to a 
normal level. In the second part, the authors analyzed chronic 
graft rejection patients. The number of anti-MICA Ab positive 
patients was significantly higher than those with stable renal 
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function (P <  0.05), and the serum creatinine levels were sig-
nificantly higher in MICA+ than in MICA− cases (P < 0.05). The 
authors also found that graft biopsy of all MICA+ cases showed 
C4d deposition (101).
Jin et al. (103) studied 53 cases of AR that showed C4d deposi-
tion in the peritubular capillaries, 50 cases of ARs without C4d 
deposition, 30 with peritubular capillaries alone, 28 with ATN, 
and 78 patients with surveillance biopsies (control group). The 
authors observed that the prevalence of PRA and anti-MICA Abs 
was increased among the peritubular capillaries alone group (30.0 
and 43.3%, respectively), albeit not significantly different from 
the group with C4d+ AR (49.1 and 39.6%, respectively). They 
also observed that the immunophenotype of infiltrating T lym-
phocytes and serum Abs (85.9% of control biopsies presented) 
had a regulatory phenotype while in the peritubular capillaries 
cohort, 93.3% of biopsies showed the cytotoxic phenotype. These 
results showed that peritubular capillaries in biopsy specimens 
from patients with early renal-allograft dysfunction could be an 
indicator of AR, especially acute humoral rejection (103).
Cai et al. (111) collected samples from 975 kidney transplant 
recipients, and they tested for C1q-fixing Abs against denatured 
HLA class I, class II, and MICA antigens. Among 169 patients 
who lost renal grafts, 44% had c1q-fixing Abs against denatured 
HLA/MICA antigens, which was significantly higher in patients 
with functioning renal transplants (25%). They concluded that 
C1q-fixing Abs were significantly associated with graft failure 
caused by AMR (72.73%) and they affirmed that only c1q-fixing 
Abs were associated with graft failure and AMR (111).
MICA Allele Epitopes and Eplets
Regarding the anti-MICA Abs, Duquesnoy et al. (118) developed 
an eplet-based version of the HLA-Matchmaker algorithm as a 
tool to assess the epitope specificity of these Abs. A repertoire of 
38 potentially immunogenic MICA eplets was selected (based on 
MICA structure molecular viewing and the amino acid sequence 
differences between MICA alleles). These eplets are based on a 
functional epitope structure (a configuration of amino acids 
within a 3 Å radius of an Ab accessible polymorphic residue on 
the molecular surface). In this study, the eplet frequencies were 
calculated from MICA allele frequencies in 1,245 European-
Americans and 605 African-Americans. Many eplets are shared 
by very similar groups of MICA alleles. For instance, the com-
bination of eplets called CMGWS “supereplet” is composed by 
36C, 129M, 206GW, and 215S epitopes and shared by the same 
group of MICA alleles (A*001, A*002, A*007, A*011, A*012, 
A*015, A*017, A*018, A*021, A*030, A*041, A*043, A*045, 
A*046, A*047, A*014, A*020, A*023, A*026, A*029, A*036, 
A*040, A*050, A*052, and A*055). The random chance that these 
eplets are a mismatch is 20.1% in African-Americans and 24.0% 
in European-Americans. Alternatively, the combination of eplets 
named AYVE “supereplet” is composed by 25AY, 129V, and 173E 
and was shared by another group of MICA alleles (A*004, A*006, 
A*008, A*009, A*010, A*016, A*019, A*024, and A*044). The 
random chance of their being a mismatch is 28.2% in African-
Americans and 20.1% in European-Americans (118).
Panigrahi et al. (82, 119) analyzed the presence of Abs against 
MICA*001, MICA*002, MICA*004, MICA*008, and MICA*009 
in serum samples of 185 patients transplanted with live related 
donor kidneys. Sixteen percent of all recipients developed anti-
MICA Abs during the posttransplant period, 83% of the patients 
whose grafts eventually failed had both anti-HLA and anti-MICA 
Abs as compared to 29% patients who had only anti-MICA Abs, 
and 11% of those without any of the Abs (HLA or MICA) (82, 
119).
Analysis of anti-MICA*001, MICA*002, MICA*004, 
MICA*008, and MICA*009 Abs in serum samples from 1,910 
kidney recipients showed that a correlation between the presence 
of anti-MICA Abs and the reduced in kidney-allograft survival 
was not influenced by the simultaneous presence of Abs against 
HLA (120). In this study, decreased renal-allograft survival is 
associated with anti-MICA Abs formed before transplantation. 
It was also found that patients with Abs against MICA before 
transplantation did not received more transfusions than patients 
without such Abs, in contrast with the Zwirner et al.’s study (76). 
So the authors speculate that cross-reactivity with substances 
from the environment may play a role in priming the immune 
system, facilitating anti-MICA Ab production (120).
Suarez-Alvarez et  al. (84) screened 284 kidney transplant 
sera for anti-MICA Abs and mapped the epitopes of MICA by 
screening a library of synthetic overlapping peptides from the 
extracellular domains of the protein against the sera from kidney 
transplant patients with anti-MICA Abs. Anti-MICA Abs were 
detected in 50 of 284 patients (17.6%), and they correlated with 
the development of AR. The authors found that nine regions 
were reactive with anti-MICA Abs. Five epitopes were located in 
constant regions (II, III, IV, VI, and IX) and were present in all 
MICA alleles, while the other four regions (I, V, VII, and VIII) 
mapped to variable sites of polymorphic amino acids among the 
different alleles products of MICA. In particular, regions V, VII, 
and VIII were the regions with the highest amino acid variability. 
Three polymorphic residues, 173 (E/K), 175 (S/G), and 181 
(R/T), had determined allele-specific epitopes. The aminoacid 
208Y and 213T, instead, contributed in the cross-reactivity 
among alleles (84).
Cox et  al. (90) identified MICA IgG Abs directed against 
MICA*001, *002, *004, *007, *008, *009, *012, *017, *018, *019, 
and *027. Analysis of 116 healthy control subjects revealed only 
one subject with anti-MICA Abs (0.9%) and five subjects (4%) 
with anti-HLA class II Abs, while in a subgroup of 227 transplant 
recipients and their donors the coproduction of Abs to HLA 
and MICA significantly associated with acute cellular rejection 
(ACR). Analysis of patients with AAMR established strong 
associations with the presence of Abs against HLA class I and 
II, but not anti-MICA. By aligning MICA allele profiles present 
in the subgroup of 227 renal graft recipients and their respective 
donors, it was possible to establish the precise position of amino 
acid mismatches that correlate strongly with MICA Ab produc-
tion. Mismatching at residues 36, 129, 173, 175, 213, and 251 
showed the strongest association with anti-MICA Ab production 
in transplant recipients, while 91, 125, 156, and 221 residues were 
also mismatched between recipients and donors, but were not 
significantly associated with anti-MICA Ab production. There 
are two immunodominant motifs: MICA-G1 is characterized by 
residues 36 cysteine (C), 129 methionine (M), 173 lysine (K), 206 
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glycine (G), 210 tryptophan (W), and 215 serine (S). Alternatively 
MICA-G2 epitopes share residues 36 tyrosine (Y), 129 valine 
(V), 173 glutamic acid (E), 206 serine (S), 210 arginine (R), and 
215 threonine (T). The majority of these recipients (10 out of 17 
individuals, 59%) developed de novo donor-specific anri-MICA 
Abs posttransplantation, and there was a significant association 
of graft dysfunction with the presence of anti-MICA DSA alone 
after 2 years. In conclusion, it was discovered that mismatching 
MICA alleles lead to the development of anti-MICA Abs in some 
renal graft recipients, and the presence of anti-MICA DSA was 
independently associated with decreased glomerular filtration 
rate (eGFR) and poorer graft outcome (90).
Tonnerre et al. (106) went beyond the usual studies of anti-
MICA Abs and focused on searching for a specific allele that 
could lead to a poorer outcome. The authors performed a study 
that showed that the MICA*008 (A5.1) molecule is a major 
antigenic determinant and target for recipient sensitization of 
kidney transplant patients. MICA A5.1 is associated with four 
alleles: *023, *028, *053, and *008. The authors divided primary 
EC cultures from transplant donors in MICA A5.1 homozygous, 
heterozygous, and control. The MICA surface expression was 
significantly higher on ECs from A5.1/A5.1 donors than from 
controls. The MICA A5.1 allele also leads to a reduction of sMICA 
and an increase in the MICA level in exosomes in ECs. Anti-
MICA (A5.1) Abs intensities in the sera of recipients with anti-
MICA Abs were not higher than intensities observed for other 
anti-MICA (control) Abs. However, when tested on EC cultures 
expressing physiologic levels of membrane-bound MICA, the 
sera only bound to ECs from MICA A5.1 donors. This seemed to 
show that anti-MICA Abs bind ECs’ targets in an allele-specific 
manner.
In fact, the combination of the donor carrying MICA A5.1 and 
the recipient having a non-MICA A5.1 allele was overrepresented 
in the group of MICA-sensitized patients compared with the 
group of non-immunized recipients (106).
Sapak et al. (108) concluded that anti-MICA Abs could not 
be responsible for the rejection if they were not directly detected 
in the transplanted graft. In the sera of 124 renal recipients, the 
authors found only 22 patients positive for anti-MICA Abs. The 
most frequent anti-MICA Abs were directed against MICA*018 
and MICA*001. MICA*008 had the highest gene frequency (31%), 
followed by MICA*002 (14%). Comparing MICA allele profiles of 
donors and anti-MICA Ab epitopes of their respective recipients, 
Sapak et  al. found a match in only in 9 donor–recipient pairs 
(41%) while the sera of the other 13 patients was negative for Abs 
against graft MICA molecules, but positive for Abs against other 
MICA antigens. The majority (59%) of anti-MICA Abs in patients 
were not donor-specific, so the authors suggested that anti-MICA 
Ab induction was not caused by renal graft allogeneic stimulation 
but was also probably stimulated by other still unknown immune 
mechanisms (108).
Sanchez-Zapardiel et al. (112) studied 727 kidney recipients. 
They found that PRA+MICA+ recipients exhibited a longer time 
to reach optimal serum creatinine level after transplantation 
(P = 0.005) had the lowest eGFR at 3 months and PRA+MICA+ 
status independently increased the risk for chronic kidney 
disease stage 5 at month 3. Pretransplant anti-MICA Abs were 
poly-specific; anti-AYVE supereplet reactivity was higher in 
HLA+MICA+ versus HLA−MICA+ patients and superior than 
anti-CMGWS supereplet within HLA+MICA+ patients. The 
authors also found that some preformed anti-MICA Abs might 
bind complement, using the C1q Luminex assay. Sanchez-
Zapardiel et al. analyzed 13 anti-MICA+ pretransplant sera that 
were positive for the C1q binding assay and one of them (serum 
3) exclusively recognized the AYVE supereplet with a strong 
reactivity against MICA*027 antigen. The authors concluded that 
these preformed anti-MICA Abs are able to mediate cell death by 
fixing and activating the complement cascade. So they speculated 
that the anti-MICA Abs might contribute to worse early kidney 
graft function (112).
Correlation between Anti-MICA Abs and Creatinine 
Levels or Estimated Glomerular Filtration Rate 
(eGRF) or Death-Censored Graft Survival (DCGSs)
Yao et al. (92) included 29 sensitized recipient patients who had 
undergone living-related donor renal transplantation between 
2007 and 2009. They found a statistical difference in postopera-
tive serum creatinine levels within 1 week between anti-MICA 
Ab-positive (135.4 ±  21.4  mol/L) and anti-MICA Ab-negative 
groups (108.6  ±  31.6  mol/L), but no significant difference 
between the two groups at discharge. To decrease the preexisting 
Abs (mainly IgG, IgM, and IgE), all recipients were treated with 
protein A immunoadsorptions, and this therapy was effective in 
decreasing anti-MICA Abs (92).
Zhang et  al. (93) studied patients receiving primary kidney 
transplants (all from deceased donors) between 2004 and 2007. 
No significant association was found between the presence of 
anti-MICA and -HLA Abs, nor between the presence of anti-
MICA Abs and 1-year graft survival rate. However, during the 
follow-up period, eGFR decreased 24.0 ± 3.4% in the anti-MICA 
Abs positive group, while it decreased only 8.4 ± 3.0% in anti-
MICA Abs negative patients. A strong correlation between the 
production of anti-MICA Abs and renal impairment was also 
found. For these reasons, the authors concluded that patients with 
anti-MICA Abs had a more rapid deterioration of graft function, 
compared to those without anti-MICA Abs (93).
In another study that did not recognize MICA as a biomarker, 
sera from 779 kidney transplant recipients was tested with two 
single-antigen flow bead assays 1  year after transplantation. 
Thirteen of the 779 patients were lost to follow-up, 50 had lost 
their graft, and 33 died with a functioning graft. The prevalence 
of anti-MICA Abs was 5.3% at 1-year posttransplantation, and 
that MICA+ patients were more frequently HLA sensitized and 
regrafted. However, 4-year DCGSs were not different between 
MICA+ and MICA− patients (97 versus 94%, P = 0.28), and 4- and 
8-year survival rates were similar in MICA+ and MICA− patients. 
Thus, the hypothesis of an independent pathogenic role for MICA 
in long-term renal graft injury was not supported, and the authors 
questioned the utility of monitoring anti-MICA Abs posttrans-
plant with single-antigen flow bead assays (94).
MICA Abs in Case Study
Narayan et al.’s (91) case study focused on a 14-year-old girl with 
branchiooto renal syndrome who underwent re-transplantation 
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with an HLA crossmatch-negative deceased donor kidney. She 
lost her first kidney transplant to chronic rejection at the age of 10 
and underwent allograft nephrectomy. She was highly sensitized, 
and to improve her chances for transplantation, she underwent 
desensitization with high-dose IVIG and rituximab. When she 
received a deceased donor renal transplant, the pretransplant 
anti-HLA Ab testing showed no anti-donor HLA Abs. The patient 
maintained good allograft function until postoperative day 10 
when she presented with fever and anuric renal failure. The only 
Ab found was donor-specific anti-MICA Ab, specifically directed 
against MICA*012 protein. Evaluation of the pretransplant 
serum revealed preformed anti-MICA*012 Abs with levels that 
were elevated both before transplant and at the time of rejection. 
Anti-MICA Abs levels declined with the initiation of plasmapher-
esis and IVIG and correlated well with normalization of renal 
function and resolution of ACR and AMR. The authors specu-
lated that the sensitization to the MICA*012 protein was caused 
by prior sensitization from the first renal transplant or previous 
infections or transfusions. The conclusion of their research is 
that donor-specific anti-MICA Abs can be associated with both 
AMR and Banff type IIA ACR and may require treatment with 
plasmapheresis (91).
Ming et al. (109) studied a patient who suffered early aggres-
sive AMR in the presence of DSA against MICA after her first 
renal transplant. The researchers found that anti-MICA–DSA in 
recipient serum could bind MICA-G1 antigens expressed in the 
cultured human umbilical cord vein endothelial cells (HUVECs). 
The recipient serum was cytotoxic to these HUVECs, but not 
against HUVECs that did not express MICA-G1 antigens in the 
presence of complement. The researchers discovered that the 
patient had been sensitized to MICA antigens and HLA, before 
transplantation, and the HLA alloantibodies were not specific to 
the first kidney donor, but the MICA alloantibodies were. In light 
of this discovery, the second renal transplant was with a negative 
MICA virtual crossmatch, and it was successful (109).
microRNA and mRNA’s Analysis
Seiler et al. (62) showed that an elevated NKG2D mRNA expres-
sion in biopsy material was correlated with the severity of AR 
and detected NKG2D+ cells located in clusters around tubules in 
biopsies derived from patients diagnosed with acute and chronic 
rejection. The expression of NKG2D mRNA was also detected 
in urinary sediments obtained 2–3 days before the AR episode. 
However, significant levels of MICA mRNA were not detected in 
the patient groups analyzed (62). For the first time, the focus was 
on the importance of the role of the NKG2D molecule, which is 
responsible for MICA signal transduction.
Another controversial paper regarding the role of MICA is the 
Racca et al.’s study (86), in which the authors obtained peripheral 
blood samples from 29 renal-transplanted patients (19 men). 
They classified patients it into three groups: AR group (9 patients 
with acute grade I/II allograft rejection), chronic rejection group 
(10 patients with chronic allograft rejection), and stable evolution 
group (10 patients with clinically stable allograft evolution). The 
authors observed that MICA mRNA levels in peripheral blood 
mononuclear cells showed similar expression levels in all groups 
evaluated and in the control group. They also found similar levels 
of MICA expression in a comparison of biopsy specimens from 
AR and nephrotoxic ATN patients. They did not find a correlation 
between MICA expression and renal graft state (86). It is interest-
ing to note that the MICA expression in biopsies did not have 
a healthy control group, while expression of MICA mRNA may 
be a posttranscriptional control that modules MICA expression 
on the cell surface. The Racca et  al.’s (86) study still represents 
an interesting opportunity to discuss the role of MICA as a 
biomarker.
Xu et al. (110) studied miR-338-5p, a microRNA downregulated 
in AMR renal allografts, and negatively correlated with BAFF. This 
molecule plays an important role in the differentiation, develop-
ment, and proliferation of B lymphocytes. BAFF could be released 
in a soluble form (sBAFF) after cleavage and would bind to BAFF 
receptor. The receptor-associated factor 3 is a sort of adaptor for 
the BAFF–BAFF-R connection, it is implicated in a signal trans-
duction, and it appeared to be a candidate target for miR-338-5p. 
In the study, 49 follow-up renal-transplanted recipients and a 
healthy control group were examined, and it was found that anti-
HLA II Ab, anti-MICA Ab, and anti-HLA + MICA mixed Abs 
were all statistically increased in recipients. Serum miR-338-5p 
was significantly downregulated in renal-transplanted recipients 
compared with healthy volunteers and was inversely correlated 
with sBAFF. The authors speculate that miR-338-5p may regulate 
the BAFF signal, and they suggested that sBAFF was significantly 
negatively correlated with anti-MICA Abs (110).
Cytomegalovirus (CMv) and Polyomavirus 
and Transplantation
Cytomegalovirus infection is the most common viral complica-
tion after renal transplantation and solid organ transplantation 
in general. One hundred ninety-six recipients who underwent 
kidney transplantation during the past 6 years were assessed with 
at follow-up of at least 12 months. In this study, it was shown that 
the activating receptor NKG2D was expressed in a significantly 
higher number of NK cells at day 0 and day 20 compared to day 
180 (P = 0.01 and P = 0.003, respectively) and compared to the 
control group (P = 0.0003 and P = 0.0004, respectively) (121). 
This finding suggests a possible mechanism for the activation of 
NKG2D that goes beyond organ rejection, but it is closely related. 
In fact, in the Hadaya et  al. (121) study, it was shown that an 
expansion of the NKG2D+ NK cell population occurred during 
acute CMV infection which decreased over time to a level very 
similar to that of the control group.
An interesting study that involved NKG2D, performed by 
Shabir et al. (117), demonstrated that CD4+CD28null T cell expan-
sion is driven by latent CMV infection inflammation. The immune 
surveillance of CMV may have an unwanted consequence in 
the development of endothelial injury, which was proven to be 
mediated by CD4+CD27−CD28null cells in in vitro experiments. 
NKG2D was upregulated on CD4+CD27−CD28null cells isolated 
from patients in this study and might have an important compo-
nent of the cytotoxic effects of these cells. In fact, CD4+CD28null 
cells were found predominantly in CMV-seropositive patients, 
and expanded in the posttransplantation period, and expressed 
markers of cytotoxicity (NKG2D and perforin) and endothe-
lial homing (CX3CR1). Isolated CD4+CD27−CD28null cells 
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previously exposed only to CMV-derived antigens showed signs 
of endothelial damage and apoptosis, and this effect was miti-
gated by NKG2D-blocking Ab. They concluded that the increase 
in CD4+CD28null cell frequencies was associated with delayed 
graft function and lower eGRF at end follow-up, and this could 
be mediated by NKG2D (117).
Another study by Tonnerre et al. (122) investigated the impli-
cation of MICA in BK polyomavirus (BKPyV) reactivation in a 
cohort of 144 transplant donor/recipient pairs including recipients 
with no reactivation (control). BKPyV is frequently reactivated 
in kidney transplant recipients receiving an immunosuppressive 
regimen and is associated with nephropathy (BKPyVAN) and 
graft rejection. They investigated the impact of the MICA A5.1 
mutation on recipient BKPyV reactivation, and they found that 
recipients carrying a non-MICA A5.1 (nA5.1) genotype trans-
planted with a kidney from a donor carrying the A5.1 MICA 
variant had a lower risk of BKPyV reactivation (P =  0.0148). 
So they speculated that MICA A5.1 could be a protective allele 
toward BKPyV infection (122). Interestingly, these researchers 
also found that the donor (A5.1)–recipient (nA5.1) combination 
was overrepresented in the group of MICA-sensitized patients, 
but in the latter, MICA A5.1 seemed to be a protective factor for 
a virus related to graft rejection (106).
CONCLUSiON
Since the MICA gene was first described, it has been the subject 
of many studies aiming to comprehend its immunobiology and 
the role it plays in fine-tuning the innate and adaptive immune 
response. MICA appears to be involved in transplant rejection, 
immune response against viruses and intracellular bacteria, 
inflammation, homeostasis of epithelia, immune response 
against tumors, and tumor immune escape mechanisms. 
However, there remain a number of open issues to be addressed 
surrounding MICA’s functions and roles. Developing and imple-
menting typing strategies for MICA alleles may increase the 
chance for positive outcomes in solid organ transplantation by 
allowing better matching. MICA’s biological function is achieved 
through its interaction with the NKG2D receptor. This activat-
ing receptor and its ligands are deeply involved in the outcomes 
of transplanted grafts, in fact, the overexpression of NKG2DLs 
could be involved in rejection episodes and can contribute to 
graft loss (44).
Various studies have shown that anti-MICA Abs, binding 
to MICA molecules expressed at the endothelial allograft cell 
surface, may have relevance to kidney transplantation outcome 
(81, 106). However, it is important to note that some studies, 
such as that of Lemy et al. (87), where the presence of anti-MICA 
Abs do not show adverse effects in renal graft outcomes (87). 
Also, MICA mRNA level analysis in blood mononuclear cells 
did not show a correlation between MICA expression and renal 
graft state (86). Seiler et  al. (62) did not find an enhancement 
of mRNA expression levels of MICA in kidney biopsies from 
patients undergoing AR or chronic allograft nephropathy, but 
they observed increased NKG2D expression. In an interesting 
study performed by Sapak et al. (108), 41% of the detected anti-
MICA Abs were donor-specific, but an astonishing 36% were 
anti-MICA Abs against self-MICA antigens and several patients 
(27%) produced both (108).
Regarding NKG2D, there are studies that report that it is pos-
sible to prolong graft survival and to prevent CD28-independent 
rejection of cardiac allografts after blocking NKG2D (123).
We can conclude that the role of MICA and NKG2D in trans-
plant outcome is not yet clear; MICA-mediated rejection prob-
ably is not just a reaction to the MICA non-self protein. The stress 
condition following a transplant causes a general inflammatory 
status in the recipient. This could increase MICA production, 
thus activating the response via the NKG2D receptor. The clini-
cal impact of these interactions will remain unclear until further 
studies are performed.
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